Scientists at nChroma Bio in Boston and institutes in Milan used epigenetic editing to place chemical tags on the hepatitis B virus genome, blocking viral gene activity without the cancer risks linked to DNA-cutting gene therapies. Tests in human liver cells, mice and monkeys showed promising result